Inhibikase Therapeutics, Inc. Common Stock (IKT) is a publicly traded Healthcare sector company. As of July 14, 2026, IKT trades at $2.28 with a market cap of $269.35M and a P/E ratio of -4.59. IKT moved +13.78% today. Year to date, IKT is -0.51%; over the trailing twelve months it is +5.95%. Its 52-week range spans $1.33 to $4.20. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces IKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest IKT news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $2.28 |
| Market Cap | $269.35M |
| P/E Ratio | -4.59 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.20 |
| 52-Week Low | $1.33 |
| Volume | 2.04M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.72M |
| Net Income | $-50.96M |
| Gross Margin | 0.00% |
6 analysts cover IKT: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.